Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates.
暂无分享,去创建一个
M. Keebler | M. Shullo | C. Sciortino | A. Zeevi | G. Hickey | Qingyong Xu | E. Horn | M. Demehin | M. Mangiola | R. Sriwattanakomen | R. Sriwattanakomen
[1] G. Serban,et al. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] David A Hildeman,et al. A prospective, iterative, adaptive trial of carfilzomib‐based desensitization , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] E. Albers,et al. Management of the sensitized pediatric heart transplant patient. , 2019, Translational pediatrics.
[4] J. Kobashigawa,et al. Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. , 2019, Circulation.
[5] J. Friedewald,et al. Prognostic tools to assess candidacy for and efficacy of antibody‐removal therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] J. Kobashigawa,et al. Crossing low-level donor-specific antibodies in heart transplantation. , 2019, Current opinion in organ transplantation.
[7] L. Potena,et al. The management of antibodies in heart transplantation: An ISHLT consensus document. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[8] J. Moreb,et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis , 2018, Leukemia & lymphoma.
[9] J. Laubach,et al. The proteasome and proteasome inhibitors in multiple myeloma , 2017, Cancer and Metastasis Reviews.
[10] Byron H. Smith,et al. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody , 2017, Transplantation.
[11] S. Yousem,et al. Proteasome Inhibitor Carfilzomib‐Based Therapy for Antibody‐Mediated Rejection of the Pulmonary Allograft: Use and Short‐Term Findings , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] M. Dimopoulos,et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. , 2017, Blood advances.
[13] J. Kobashigawa,et al. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] A. Israni,et al. OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] A. Kfoury,et al. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] J. Patel,et al. Desensitization strategies in adult heart transplantation-Will persistence pay off? , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[17] P S Heeger,et al. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation‐05 Study , 2016, American Journal of Transplantation.
[18] H. Goldschmidt,et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. , 2016, The Lancet. Oncology.
[19] J. Friedewald,et al. Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] G. Bhat,et al. Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices , 2015, Clinical transplantation.
[21] E. Reed,et al. Reduced HLA Class II antibody response to proteasome inhibition in heart transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[22] Aspire Investigators,et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .
[23] R. Alloway,et al. Prospective Iterative Trial of Proteasome Inhibitor‐Based Desensitization , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] R. Montgomery,et al. Differential Effect of Bortezomib on HLA Class I and Class II Antibody , 2014, Transplantation.
[25] X. Jouven,et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.
[26] W. Kremers,et al. LVAD Implant as a Bridge to Heart Transplantation Is Associated with Allosensitization as Measured by Single Antigen Bead Assay , 2013, Transplantation.
[27] D. Monos,et al. Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[28] J. Lunz,et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] V. Sharma,et al. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. , 2012, Clinical transplants.
[30] E. Reed,et al. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[31] G. Berry,et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[32] E. Reed,et al. The long‐term outcome of treated sensitized patients who undergo heart transplantation , 2011, Clinical transplantation.
[33] Ronny Gustafsson,et al. Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies , 2010, Transplantation.
[34] N. Pallet,et al. Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[35] M. Rose,et al. Clinical relevance of complement-fixing antibodies in cardiac transplantation. , 2009, Human immunology.
[36] S. Russell,et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. , 2007, The Annals of thoracic surgery.
[37] M. Fishbein,et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[38] M. Oz,et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. , 1999, Circulation.
[39] L. Lambert,et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. , 1996, Circulation.